share_log

HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance

Benzinga Real-time News ·  Aug 19, 2022 16:06

Biotech psychedelics companyHAVN Life Sciences Inc. (OTC:HAVLF)recently closed the initial tranche of its financing pact with innovative fundAlpha Blue Ocean ("ABO"), previously announced on July 21, 2022.

Since its creation in 2017, ABO hasexecuted more than $1.5 billion in financial commitmentsand more than 90 ‎transactions, mostly within the life sciences sector, all around the globe.

Following the current first-tranche closing, HAVN issued to theinvestment fund managed by ABO "Global Corporate Finance Opportunities 17"a total $1,100,000 principal amount of senior unsecured convertible debenture as well as 189,393 common share purchase warrants for net proceeds of approximately $420,000.

Theconvertible debenture may...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment